In a recent government meeting, significant discussions centered around two key legislative measures affecting pharmacy practices in California.

The first measure, Senate Bill 1365, aimed to adjust the pharmacist to pharmacy technician ratio from the current 1:1 or 1:2 to 1:4. However, after extensive deliberation during previous committee and board meetings, members expressed concerns about the implications of such a change. Consequently, the measure was held in the Senate Appropriations Committee and will not advance further, with no action required from the board at this time. The board plans to continue discussions on this topic in future meetings.

The second measure, Senate Bill 1468, proposes allowing practitioners not specifically registered to conduct narcotic treatment programs to dispense a three-day supply of narcotic drugs under certain conditions. The board has established a support position for this bill, which has been amended to clarify that it does not apply to the veterinary medical board. Public comments highlighted concerns regarding the bill's guidance on dispensing methadone in inpatient settings, emphasizing the need for clarity in California law regarding this practice.

Additionally, the board addressed House Resolution 58, which urges the California Health and Human Services Agency to hold pharmaceutical companies accountable for ADHD medication shortages. While the board acknowledged the resolution, it noted that drug shortages generally fall outside its purview.

The meeting concluded with a review of the board's strategic goals, particularly regarding provider status for pharmacists. Members discussed the importance of clarifying the board's position on provider status at both state and federal levels, especially concerning Medicare reimbursement.

The next board meeting is scheduled for April 10, 2025, as members continue to navigate these critical issues impacting pharmacy practice and patient care in California.